Insight

ctDNA during perioperative ChT in resectable gastric/GEJ cancer, summarised by Erman Akkus

Erman Akkus/X

Oct 9, 2024, 16:44

ctDNA during perioperative ChT in resectable gastric/GEJ cancer, summarised by Erman Akkus

Erman Akkus shared a post on X:

“ctDNA during perioperative ChT in resectable gastric/GEJ cancer

ctDNA detection rates
56% at baseline
37% After 1cycle ChT

25% after preoperative chemotherapy 15% after resection
Detection of ctDNA after 1 cycle of ChT -> RFSOS
Detection of ctDNA after surgery -> RFSOS

Correlations with pathologic responses?
ctDNA after adjuvant ChT?”

Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer

Authors: Cecilie Riis Iden, et al.

ctDNA during perioperative ChT in resectable gastric/GEJ cancer, summarised by Erman Akkus

Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.

cancer cancer awareness cancer care Cancer research Cecilie Riis Iden DNA Erman Akkus fight against cancer gastroesophageal junction cancer Global fight against cancer OncoDaily Oncology

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology